Ryzodeg (Insulin Degludec/Insulin Aspart) Clinical Use
Direct Recommendation
Start Ryzodeg at 10 units once daily with your patient's largest carbohydrate-containing meal, titrate by 2 units every 3 days based on fasting glucose targets, and intensify to twice-daily dosing when A1C remains above goal despite adequate once-daily dosing. 1, 2
Initiation Strategy
When to Start Ryzodeg
Ryzodeg should be considered as a first-line insulin option in:
- Insulin-naive patients with A1C >8.5% despite optimal oral medications 2
- Severe hyperglycemia (A1C >10% or glucose ≥300 mg/dL) 3
- Patients with significant postprandial hyperglycemia where basal insulin alone would be insufficient 1
The 2025 ADA guidelines support initiating insulin when injectable therapy is needed, though they don't specifically mandate Ryzodeg over other options 3. However, expert consensus strongly supports Ryzodeg as preferable to basal-only insulin when postprandial control is a concern 1, 2.
Starting Dose
10 units once daily with the main meal (the meal with the highest carbohydrate content) 1, 2
Lower starting doses (4-6 units) should be used in:
- Patients with cardiac comorbidities
- Patients with renal impairment
- Elderly patients at higher hypoglycemia risk 4
Titration Protocol
Weekly Titration Algorithm
Increase by 2 units every 3 days until fasting plasma glucose reaches individualized target 3, 1
- Monitor fasting glucose as the primary titration guide
- Set patient-specific FPG goals based on age, comorbidities, and hypoglycemia risk 3
- For hypoglycemia: Identify the cause; if unclear, reduce dose by 10-20% 3
This aligns with the ADA's evidence-based basal insulin titration approach, which Ryzodeg follows for its basal component 3.
Treatment Intensification
When to Intensify to Twice-Daily Dosing
Intensify from once-daily to twice-daily Ryzodeg when:
- A1C remains above goal despite adequate once-daily titration
- Elevated postprandial glucose at meals other than the main meal
- Bedtime-to-morning glucose differential is high (signals overbasalization) 3, 1
How to Split to Twice-Daily
Do NOT split 50:50 - instead, match insulin doses to the carbohydrate content of each meal 4
Practical approach:
- Continue the established dose with the largest meal
- Add 4-10 units with the second-largest meal
- Titrate each dose independently based on pre-meal and 2-hour postprandial glucose 1, 4
Switching to Ryzodeg
From Basal Insulin
- Unit-to-unit conversion from the total daily basal dose
- Give as once-daily with the main meal initially 1, 5
From Premixed Insulin (Once or Twice Daily)
From Basal-Bolus Regimen
- Calculate 80% of total daily insulin dose as the starting Ryzodeg dose
- Split between 1-2 daily doses based on meal patterns 1, 5
- This reduction accounts for the ultra-long action of degludec and reduces hypoglycemia risk
Combination Therapy Considerations
With GLP-1 Receptor Agonists
The 2025 ADA guidelines recommend considering GLP-1 RA + insulin combinations (including fixed-ratio products like IDegLira) when A1C is above goal 3. When adding GLP-1 RAs to Ryzodeg:
- Reduce Ryzodeg dose by 20-30% to prevent hypoglycemia 1
With SGLT2 Inhibitors
- Reduce Ryzodeg dose when adding SGLT2 inhibitors 1
With Sulfonylureas
- Discontinue or reduce sulfonylurea dose when starting Ryzodeg to minimize hypoglycemia risk 1
Special Populations
Ramadan Fasting
- Switch to Ryzodeg early (weeks before Ramadan) for adequate titration 4
- Reduce breakfast/lunch dose by 30-50% and give at sahur (pre-dawn meal)
- Maintain dinner dose unchanged and give at iftar (evening meal) 4
Hospitalized Patients
Recent 2024 data shows that inpatients on Ryzodeg have similar hypoglycemia rates but higher hyperglycemia compared to traditional premixed insulins, likely due to less frequent twice-daily dosing 6.
Hospital management approach:
- Continue Ryzodeg if patient is eating regular meals
- Consider switching to basal-bolus or sliding scale if NPO or meal timing is unpredictable
- The ultra-long duration of degludec (>42 hours) makes rapid dose adjustments difficult 6
Contraindications
Note: The FDA label provided 7 appears to be for hydrochlorothiazide, NOT Ryzodeg - this is a data error.
Based on standard insulin contraindications and clinical practice:
- Hypersensitivity to insulin degludec, insulin aspart, or excipients
- Episodes of hypoglycemia (do not administer during active hypoglycemia)
- Use caution in patients with hypoglycemia unawareness
Alternative Regimens
When Ryzodeg is not appropriate, the 2025 ADA guidelines provide a clear hierarchy 3:
- Basal insulin alone (degludec, glargine, detemir, or NPH) - simpler, lower cost, but doesn't address postprandial glucose
- Basal + GLP-1 RA (or fixed-ratio IDegLira/iGlarLixi) - preferred when cardiovascular benefit is needed
- Traditional premixed insulins (70/30,75/25) - similar concept but with shorter basal duration and less flexibility
- Basal-bolus regimen - most intensive, highest efficacy, but 4+ injections daily
Key Clinical Pitfalls
Meal Timing Flexibility
Ryzodeg offers flexibility in administration timing (can be given with any meal, not necessarily the same meal daily), but patients must understand the "main meal" concept - the meal with the most carbohydrates 1, 4.
Avoiding Overbasalization
Watch for signs that signal need for intensification rather than continued basal titration 3:
- High bedtime-to-morning glucose differential
- Recurrent hypoglycemia
- High glucose variability despite adequate fasting control
Weight Gain
Expect modest weight gain (1-2 kg), which is less than with traditional premixed insulins but more than basal-only regimens 8. Consider adding GLP-1 RA if weight is a concern 3.
Dose Adjustments Take Time
The ultra-long half-life of degludec means steady state is reached in 2-3 days - avoid daily dose changes, which can lead to stacking and delayed hypoglycemia 1.